This Report provided by 24 Market Reports is about, the colorectal cancer (CRC) market considering the sales of both branded treatments and generic chemotherapy is expected to experience a moderate growth between 2015 and 2025. The main drivers of growth will be the expected increased number of diagnosed CRC incidence and the launch and uptake of premium-priced therapies.
Download Sample Brochure @ http://bit.ly/2dkqhan DelveInsight’s Prostate cancer - Market Insights, Epidemiology and Market Forecast-2020” Reports provides an overview of the disease and global market trends of the %Indication"% for the seven major markets ie: United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the therapeutics market revenue; average cost of therapy, treatment practice and Prostate cancer forecasted market share for ten years to 2020 segmented by seven major markets. In addition, the report also includes global forecast of epidemiology of Prostate cancer till 2020. Read Analysis @ http://bit.ly/2erzZcN
Big Market Research present “PharmaPoint: Prostate Cancer - Global Drug Forecast and Market” Size, Share, Industry Trends, Demand, Analysis, Research, Report, Company Profiles, Forecast to 2023. Visit for more info @ http://www.bigmarketresearch.com/pharmapoint-prostate-cancer-global-drug-forecast-and-analysis-to-2023-market Prostate cancer is the second most common cancer in men worldwide, after skin cancer. It accounts for 15% of all the cancers diagnosed in men, and thus represents a huge burden on healthcare systems. While patients diagnosed with early-stage, localized prostate cancer can be cured, patients who are diagnosed with or progress to castration-resistant prostate cancer (CRPC) have no curative options.
A report from TheBusinessResearchCompany shows that the "Global Prostate Cancer Drugs Market 2019" is expected to grow to $10.38 billion at a CAGR of 8.1% through 2022. Read more at https://bit.ly/2k8Tye9
A recent report published by TheBusinessResearchCompany on Prostate Cancer Drugs Market provides in-depth analysis of segments and sub-segments in the global as well as regional. http://bit.ly/2Utt4nh
This report studies the global Prostate Cancer Drugs market, analyzes and researches the Prostate Cancer Drugs development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like AbbVie Astellas Pharma Astra Zeneca Johnson & Johnson Sanofi
Get World Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics - Market Opportunity and Forecast, 2014 - 2020 market research report Published by Allied Market Research. The Report is available at $4515 for Single User, and $10680 for Corporate User
iGATE RESEARCH report titled “Global Prostate Cancer Therapeutics Market to 2020” is a 76 page report with 43 Figures and 4 Tables. This report analyses the Prostate Cancer Therapy Market, Prostate Cancer Drugs Market, driving factors and challenges for prostate cancer market. Click here to view the complete report: http://www.igateresearch.com/ProductDetail.php?pd_name=Global%20Prostate%20Cancer%20Therapeutics%20Market%20to%202020 Contact US iGATE Research PVT LTD Ravi Sinha Sales Manager Marketing and Sales Divison Email: ravi.sinha@igateresearch.com Contact: +91-858-684-0791, +91-706-527-9335 (INDIA) Web: www.igateresearch.com
The report analyzes innovation in prostate cancer, in the context of the overall pipeline and current market landscape. In addition, it analyzed the deals landscape surrounding first-in-class products in prostate cancer, and pinpoints opportunities for in-licensing. For Further Details : http://www.bigmarketresearch.com/frontier-pharma-prostate-cancer-identifying-and-commercializing-first-in-class-innovation-market
Castration-Resistant Prostate Cancer (CRPC) or Hormone Refractory Prostate Cancer (CRPC), a type of prostate cancer that typically recurs after administering androgen deprivation therapy (ADT), is gaining prominence in the prostate cancer market. The global CRPC market is poised to expand at a significant pace, owing to high unmet clinical need, limited survival benefits, growing prevalence rates and fast emerging treatment modifications.
Download Sample Brochure@ http://tinyurl.com/j3jt7ly Marketintelreports, ‘Prostate Cancer - Pipeline Review, H2 2015’, provides an overview of the Prostate Cancer’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Prostate Cancer and special features on late-stage and discontinued projects.
Analyze Future: Prostate Cancer Treatment Drugs Markets in China To Get More Details @ http://www.analyzefuture.com/prostate-cancer-treatment-drugs-in-china-market China's demand for Prostate Cancer Treatment Drugs has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2003, 2008 and 2013) and long-term forecasts through 2018 and 2023 are presented. Major producers in China are profiled.
iGATE RESEARCH report titled “Global Prostate Cancer Therapeutics Market to 2020” is a 76 page report with 43 Figures and 4 Tables. This report analyses the Prostate Cancer Therapy Market, Prostate Cancer Drugs Market, driving factors and challenges for prostate cancer market. Click here to view the complete report: http://www.igateresearch.com/ProductDetail.php?pd_name=Global%20Prostate%20Cancer%20Therapeutics%20Market%20to%202020 Contact US iGATE Research PVT LTD Ravi Sinha Sales Manager Marketing and Sales Divison Email: ravi.sinha@igateresearch.com Contact: +91-858-684-0791, +91-706-527-9335 (INDIA) Web: www.igateresearch.com
Prostate Cancer (PC) is a disease predominately of the elderly with 60% of cases diagnosed in men aged 65 or over. Prostate cancer is slow growing, and asymptomatic at its earliest stages.
During the forecast period from 2012 - 2022, the growth of the UC market will be driven largely by the entry of Johnson & Johnsons (J&Js) Simponi and Takedas Entyvio, which will lead to an increase in the overall number of patients being treated with biologics in the US, 5EU, Japan, and Canada.
Metastatic Prostate Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015, Report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the Metastatic Prostate Cancer. Browse full report @ http://bit.ly/1wdcwzs
Epilepsy is a brain disorder characterized by spontaneously occurring and recurrent seizures. The market is heavily driven by the sales of antiepileptic drugs (AEDs) targeted at seizure reduction. The AED market is currently dominated by UCB’s Keppra and GlaxoSmithKline’s Lamictal. Although both drugs have experienced significant generic erosion, they form the mainstay of epilepsy treatment in the nine markets and will continue to have significant market share during the forecast period. See Full Report @ bit.ly/1vM6jVN
Global Prostate cancer Information, by product type hormone therapy, targeted therapies, therapeutic vaccines and others), end users (hospitals, clinics and others) - 2027
Get a sample brochure @ http://tinyurl.com/gpkg4bf Castration-Resistant Prostate Cancer (CRPC) or Hormone Refractory Prostate Cancer (CRPC), a type of prostate cancer that typically recurs after administering androgen deprivation therapy (ADT), is gaining prominence in the prostate cancer market. The global CRPC market is poised to expand at a significant pace, owing to high unmet clinical need, limited survival benefits, growing prevalence rates and fast emerging treatment modifications. The market growth would pivot around the novel breakthrough treatments responsible for reaping survival benefits. The survival benefit would be instrumental in governing the peak sales and market penetration of novel approved drugs.The global CRPC market is expected to reach $9.5 billion by 2020, at a CAGR of 9.1% during the forecast period (2015-2020).
The key objective is to present a comprehensive analysis of the current state of prostate cancer therapy and technology, utilization of the various therapeutic and diagnostic modalities to prevent and treat prostate cancer. The report’s focus is on prostate cancer treatment strategies such as hormone therapy, chemotherapy, radiotherapy and immunotherapy, and other treatment modalities and testing and screening methods.
Prostate cancer is cancer which occurs in a man's prostate. It is a small walnut-shaped gland that produces the seminal fluid that nourishes and transports sperm. It is one of the most common types of cancer in men.
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015, Report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer. Browse full report @ http://bit.ly/1Ms2HSk
These compounds will challenge the current biologics in an attempt to dislodge the stronghold of the TNF inhibitors, as they aim to tap into the lucrative portion of the CD therapeutics market. If their promising safety and efficacy profiles translate to clinical practice once they enter the market, their launch will be to the detriment of the existing market leaders, Remicade (infliximab) and Humira (adalimumab).
The report on Prostate Cancer Therapeutics Market by Infinium Global Research analyzes the Prostate Cancer Therapeutics Market over the period of 2017 to 2023. This report also provides detailed qualitative and quantitative analyses of the market dynamics, market size and future trends in Global Prostate Cancer Therapeutics Market. It will help a lot of decision makers to develop strategies and find new opportunities in the Global Prostate Cancer Therapeutics Market.
During the forecast period from 2012-2022, the growth of the ulcerative colitis market will be driven largely by the entry of Johnson & Johnsons (J&Js) Simponi and Takedas Entyvio, which will lead to an increase in the overall number of patients being treated with biologics in the US, 5EU, Japan, and Canada. See More: http://goo.gl/tW6DQL
Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation. The disease is often asymptomatic, but infected patients may experience fatigue, joint pain, itchy skin or jaundice. There is no effective vaccine against HCV, so the market is driven by therapeutics. See Full Report @ bit.ly/ZrFfRz
Research Beam added report on “Global Prostate Cancer Vaccine Industry 2015”. 2015 Global Prostate Cancer Vaccine Industry Report is a professional and in-depth research report on the world's major regional market conditions of the Prostate Cancer Vaccine industry, focusing on the main regions (North America, Europe and Asia) and the main countries (United States, Germany, Japan and China) . Enquiry @ http://www.researchbeam.com/global-prostate-cancer-vaccine-industry-2015-research-report-market/enquire-about-report
LifeScienceIndustryResearch.com adds “Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline Review, H1 2015” to its store. This report provides comprehensive information on the therapeutic development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with comparative analysis at various stages.
The new PharmaPoint Drug Evaluation report, “Lonsurf (Colorectal Cancer) - Forecast and Market Analysis to 2023”. For more details : http://goo.gl/jGIpRr
Complete report is available @ http://goo.gl/gufzCs. Kadcyla (ado-trastuzumab) is Roche’s third HER2-targeted mAb, approved by the FDA in February 2013, by the Japanese MHLW in September 2013, and by the EMA in November 2013, for the second-line treatment of metastatic HER2-positive breast cancer. Kadcyla is an antibody-drug conjugate consisting of trastuzumab covalently linked to the microtubule inhibitor, DM1 (mertansine) via a non-reducible thioether linkage (MCC).
GlobalData has released its new Country report, “PharmaPoint: Dry Eye Syndrome - India Drug Forecast and Market Analysis to 2022”. Dry eye syndrome (DES), or keratoconjunctivitis sicca, is a multifactorial disease of the eye caused by dryness, decreased tear production, or increased tear film evaporation. DES, which is often referred to simply as dry eye, is the most prevalent form of ocular discomfort and irritation.
Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The stage of CML is classified as chronic, accelerated or blast phase, ranging from least to most severe. Multiple BCR-ABL tyrosine kinase inhibitors (TKIs) are approved, and are the standard of care for CML. TKIs have transformed most cases of the disease into a manageable, chronic condition. As a result, patients’ survival rates and the prevalence of CML are increasing, placing a growing burden on global healthcare systems. https://www.bharatbook.com/healthcare-market-research-reports-470146/drug-healthcare-global-7.html
April 21st, 2015 – Navi Mumbai, India: Market Reports on India presents the report on "PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022" the coming decade could see the launch of the first biologic, which will set a precedent and pave the way for others to follow suit.
“PharmaPoint: Alzheimer’s Disease - India Drug Forecast and Market Analysis to 2022”. There are no long-term effective therapies for Alzheimer’s Disease (AD), so this remains at the top of the list for unmet needs. While physicians agree that symptomatic therapies are relatively safe and effective, these therapies are still lacking because of they cannot maintain their effects and lack mechanisms that alter the course of the disease.
Big Market Research present “PharmaPoint: Melanoma - Global Drug Forecast and Market Analysis” Size, Share, Industry Trends, Demand, Analysis, Research, Report, Company Profiles, Forecast to 2023. Visit for more info @ http://www.bigmarketresearch.com/pharmapoint-melanoma-global-drug-forecast-and-analysis-to-2023-market Melanoma is the deadliest and most aggressive form of skin cancer. The major treatments for melanoma are categorized into immunotherapies and BRAF mutation-targeted therapies. GlobalData estimates the 2013 sales for melanoma at approximately $1.34 billion across the 8MM covered in this report. The market will increase by four-fold over the forecast period, reaching $5.64 billion in 2023 at a CAGR of 15.5%.
The entire market for microvascular complications of diabetes (MCD) diabetic nephropathy, retinopathy, and neuropathy is facing an extremely high level of unmet need across the 7MM (US, 5EU and Japan). Despite its enormous potential, the MCD market is facing the major global barrier in the sparsely populated pipeline. The diabetic retinopathy segment of the market has recently seen rapid uptake of novel anti-VEGF therapies and is experiencing a strong growth. On the other hand, the diabetic neuropathy and nephropathy segments face the barrier in and increasing number of generic competitors.
Get a detailed report at http://www.marketoptimizer.org/pharmapoint-parkinsons-disease-japan-drug-forecast-and-market-analysis-to-2022.html . Parkinson’s disease is a progressive condition that is characterized by bradykinesia, muscular rigidity, tremor, and postural instability.
Cancer Disparities Research Partnership Program Process & Outcome Evaluation Purpose of Evaluation Measure relevance, effectiveness, and impact of CDRP Program in a ...
Get a detailed report at http://www.marketoptimizer.org/pharmapoint-parkinsons-disease-us-drug-forecast-and-market-analysis-to-2022.html . Parkinson’s disease is a progressive condition that is characterized by bradykinesia, muscular rigidity, tremor, and postural instability. Some needs will be met during the forecast period from 2012-2022, while others, such as the need for disease-modifying drugs, will remain. Researcher expects that advancements will be made in levodopa administration and that four new molecular entities will be introduced to the market by 2022, these factors along with increased patient numbers from an aging population will drive the market during the forecast period.
Get a detailed report at http://www.marketoptimizer.org/pharmapoint-parkinsons-disease-5eu-drug-forecast-and-market-analysis-to-2022.html . As the second most common neurodegenerative disorder, Parkinson’s disease may affect individuals of any age but prevalence is increased with age and it is most common in the elderly. Dopaminergic therapies have been fairly effective in treating bradykinesia, but several unmet needs remain. Some needs will be met during the forecast period from 2012-2022, while others, such as the need for disease-modifying drugs, will remain. GlobalData expects that advancements will be made in levodopa administration and that four new molecular entities will be introduced to the market by 2022, these factors along with increased patient numbers from an aging population will drive the market during the forecast period.
Only one older generation drug with modest efficacy had been available until the recent arrival of two new therapies that could potentially change the prescribing landscape. Will these drugs make a significant impact on the Obesity market? Which drugs are used off-label for the treatment of obesity?
Racial/Ethnic Disparities in Cancer Incidence, Survival and Treatment Linda C. Harlan, PhD, MPH National Cancer Institute Division of Cancer Control and Population ...
Cancer Bronchique Non Petites Cellules Bilan fonctionnel et d op rabilit Docteurs J SEIGNEUR-D BRAUN Clinique Claude Bernard METZ INTRODUCTION Principes du bilan ...
This report studies Prostate Cancer Medicine in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022.
Renub Research has announced the addition of the "http://www.renub.com/global-prostate-cancer-therapeutics-market-to-2020-487-p.php" report to its offering
The Industry Report provides a clear picture of the Current Market Scenario which includes past and estimated future size with respect to value and volume, technological advancement, macro economical and governing factors in the market.
The global market for prostate cancer products reached nearly $47.2 billion in 2016 and should reach nearly $65.1 billion in 2021, with a compound annual growth rate (CAGR) of 6.6%. Report Scope: The scope of this study is testing, screening technology and also therapeutics markets for prostate cancer. The report also includes the regulatory environment, current technologies, new technologies, prostate cancer incidence, market projections and market share, along with latest trends and new developments. Get More Information sample: https://www.trendsmarketresearch.com/report/sample/11795
Prostate cancer is the occurrence of cancerous tumors in the prostate region of a man. The initial stage of the cancer remains within the prostate region where it is not expected to cause much harm. However, once it starts spreading it can turn fatal. The global prostate cancer market is riding on the advantages provided by advanced technologies and could achieve substantial market growth during the forecast period (2018-2027). Get Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/1580
The prostate cancer pipeline is among the largest in the pharmaceutical industry with 484 products in active development across all stages. For More Details: http://goo.gl/cIMtf5
Big Market Research, Global Pharma Point Colorectal Cancer Drug Market Size, Share, Trends, Application, Forecast, Demand, Analysis, Research, Report, Opportunities, Segmentation to 2023. Colorectal cancer (CRC) is the second leading cause of mortality among cancer patients in the world and is the third most diagnosed cancer globally, and thus represents a huge burden on healthcare systems. By 2023, the end of the forecast period, GlobalData projects CRC sales to rise to $8.11 billion in the 8MM, at a moderate Compound Annual Growth Rate (CAGR) of 4.9%. Major drivers of the growth of the CRC market over the forecast period include increasing CRC incident cases, the launch of premium-priced adjuvant and maintenance treatments for first-line metastatic disease, and the launch of pipeline agents for later-line CRC. Annualized Colorectal cancer therapeutics market revenue, annual cost of therapy, and treatment usage patterns in eight patient segments, forecast from 2013 to 2023.
Big Market Research, Global PharmaPoint HER2-Positive Breast Cancer Drug Market Size, Share, Trends, Application, Forecast, Demand, Analysis, Research, Report, Opportunities, Segmentation, to 2023. HER2-positive breast cancer is the second most common cancer in the world and the most common cancer in women worldwide. This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the HER2-positive breast cancer market, with coverage of multiple settings of the disease including neoadjuvant, adjuvant, first-, second-, third-, and fourth-line metastatic. This report forecasts that the two monoclonal antibodies that also target the HER2 receptor will ensure Roche still occupies over 95% of the market in 2023. The challenge for new entrants into the HER2-positive market is to find patient populations that are currently underserved, and can work cooperatively with Roche’s targeted therapies.
Big Market Research, PharmaPoint: Global Asthma Drug Market Size, Share, Strategies, Trends, Application, Forecast, Demand, Analysis, Research, Report, Opportunities. Big Market Research added a new research report "PharmaPoint: Asthma - Global Drug Forecast and Market Analysis to 2023". Asthma accounts for approximately 250,000 deaths around the world annually, deaths that otherwise could be easily prevented through appropriate treatment The asthma market saw very slow growth over the past decade. The largest unmet needs mainly reflect the high level of heterogeneity of the disease, the lack of patient compliance with the standard therapies, and the high cost of medications for asthma treatment. In addition, there is a lack of diagnostic tools to provide a reliable diagnosis of asthma in young children. Annualized asthma therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2013 and forecast for ten years to 2023.
Asthma accounts for approximately 250,000 deaths around the world annually, deaths that otherwise could be easily prevented through appropriate treatment The asthma market saw very slow growth over the past decade, as it has become saturated with relatively efficacious standard therapies, such as short-acting beta-agonists (SABAs), inhaled corticosteroids (ICSs), inhaled corticosteroids and long-acting beta-agonists (ICS/LABAs), and leukotriene modifiers, and has also been facing increasing generic competition. See Full Report @ bit.ly/12yBegp